Marshall Wace, LLP Intercept Pharmaceuticals, Inc. Transaction History

Marshall Wace, LLP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$9.99 - $18.71 $6,793 - $12,722	680 Added 3.12%	22,500 $417,000
Q2 2023 Aug 14, 2023	SELL	$9.17 - $19.29 $839,064 - $1.77 Million	-91,501 Reduced 80.74%	21,820 $241,000
Q1 2023 May 15, 2023	BUY	$12.53 - $21.71 $1.42 Million - $2.46 Million	113,321 New	113,321 $1.52 Million
Q2 2022 Aug 15, 2022	SELL	$11.23 - $19.59 $301,368 - $525,717	-26,836 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$13.37 - $17.79 $189,747 - $252,475	-14,192 Reduced 34.59%	26,836 $436,000
Q4 2021 Feb 14, 2022	SELL	$14.28 - $19.53 $986,133 - $1.35 Million	-69,057 Reduced 62.73%	41,028 $669,000
Q3 2021 Nov 15, 2021	BUY	$12.99 - $20.47 $1.43 Million - $2.25 Million	110,085 New	110,085 $1.64 Million
Q2 2021 Aug 13, 2021	SELL	$15.46 - $24.5 $1.19 Million - $1.88 Million	-76,723 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$19.33 - $37.75 $63,595 - $124,197	3,290 Added 4.48%	76,723 $1.77 Million
Q4 2020 Feb 16, 2021	BUY	$24.48 - $42.47 $852,026 - $1.48 Million	34,805 Added 90.1%	73,433 $1.81 Million
Q3 2020 Nov 16, 2020	BUY	$39.09 - $53.44 $1.51 Million - $2.06 Million	38,628 New	38,628 $1.6 Million

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.